P. Delmas

Publications700
h-index145
Citations76,034
Highly Influential Citations2,319
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • P. Meunier
  • 402 Publications, 43,825 Citations
  • C. Christiansen
  • 758 Publications, 57,004 Citations
  • H. Genant
  • 1,073 Publications, 82,023 Citations
  • P. Garnero
  • 239 Publications, 24,289 Citations
  • Publications
  • Influence
Bone quality--the material and structural basis of bone strength and fragility.
This review discusses advances in knowledge regarding the composition and structure of bone, the modeling and remodeling of bone, the formation of bone during growth and its reconstruction in adults,… Expand
  • 1,670
  • 67
  • PDF
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial
Raloxifene is a selective estrogen receptor modulator that has been shown to prevent bone loss in postmenopausal women. Whether it also reduces the risk of fracture remains uncertain, prompting the… Expand
  • 1,023
  • 65
In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography.
CONTEXT Assessment of trabecular microarchitecture may enhance the prediction of fracture risk and improve monitoring of treatment response. A new high-resolution peripheral quantitative computed… Expand
  • 989
  • 64
  • PDF
European guidance for the diagnosis and management of osteoporosis in postmenopausal women
SummaryGuidance is provided in a European setting on the assessment and treatment of postmenopausal women at risk of fractures due to osteoporosis.IntroductionThe International Osteoporosis… Expand
  • 805
  • 64
  • PDF
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
BACKGROUND A single infusion of intravenous zoledronic acid decreases bone turnover and improves bone density at 12 months in postmenopausal women with osteoporosis. We assessed the effects of annual… Expand
  • 826
  • 57
Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal Osteoporosis
Oral daily (2.5 mg) and intermittent ibandronate (between‐dose interval of >2 months), delivering a similar cumulative exposure, were evaluated in 2946 osteoporotic women with prevalent vertebral… Expand
  • 1,075
  • 54
  • PDF
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.
BACKGROUND Denosumab is a fully human monoclonal antibody to the receptor activator of nuclear factor-kappaB ligand (RANKL) that blocks its binding to RANK, inhibiting the development and activity of… Expand
  • 1,612
  • 53
  • PDF
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation…
CONTEXT Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known. OBJECTIVE To… Expand
  • 2,543
  • 48
  • PDF
Vitamin D3 and Calcium to Prevent Hip Fractures in Elderly Women
Abstract Background. Hypovitaminosis D and a low calcium intake contribute to increased parathyroid function in elderly persons. Calcium and vitamin D supplements reduce this secondary… Expand
  • 2,122
  • 37
Predictive Value of BMD for Hip and Other Fractures
The relationship between BMD and fracture risk was estimated in a meta‐analysis of data from 12 cohort studies of ∼39,000 men and women. Low hip BMD was an important predictor of fracture risk. The… Expand
  • 1,176
  • 35